EyePoint Pharmaceuticals Inc

More Details of EyePoint Pharmaceuticals Inc Company

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Company Info

Ticker SymbolEYPT

Company nameEyePoint Pharmaceuticals Inc

IPO dateJan 27, 2005

CEODr. Jay S. Duker, M.D.

Number of employees165

Security typeOrdinary Share

Fiscal year-endJan 27

Address480 Pleasant Street, Suite C400

CityWATERTOWN

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code02472

Phone16179265000

Websitehttps://eyepointpharma.com/

Ticker SymbolEYPT

IPO dateJan 27, 2005

CEODr. Jay S. Duker, M.D.

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

41.78K

--

Dr. Reginald J Sanders, M.D.

Non-Executive Independent Director

--

Mr. Fred Hassan

Non-Executive Independent Director

--

Mr. Stern

Investor Relations

--

Name

Name/Position

Position

Shareholding

Change

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

YUTIQ

3.10M

7.16%

By RegionUSD

Name

Revenue

Proportion

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

YUTIQ

3.10M

7.16%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

Cormorant Asset Management, LP

12.08%

Suvretta Capital Management, LLC

9.87%

Adage Capital Management, L.P.

9.87%

BlackRock Institutional Trust Company, N.A.

6.67%

Franklin Advisers, Inc.

6.19%

Other

55.32%

Shareholders

Proportion

Cormorant Asset Management, LP

12.08%

Suvretta Capital Management, LLC

9.87%

Adage Capital Management, L.P.

9.87%

BlackRock Institutional Trust Company, N.A.

6.67%

Franklin Advisers, Inc.

6.19%

Other

55.32%

Shareholder Types

Shareholders

Proportion

Hedge Fund

39.03%

Investment Advisor

26.94%

Investment Advisor/Hedge Fund

24.54%

Research Firm

4.28%

Individual Investor

3.51%

Venture Capital

3.42%

Private Equity

1.96%

Bank and Trust

1.11%

Pension Fund

0.16%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

385

78.45M

113.85%

-10.49M

2025Q1

386

76.27M

110.90%

-11.90M

2024Q4

373

75.75M

111.39%

+202.32K

2024Q3

358

60.55M

112.89%

-8.01M

2024Q2

345

60.80M

116.35%

-2.75M

2024Q1

328

57.32M

114.97%

+528.95K

2023Q4

282

52.72M

108.16%

+11.49M

2023Q3

239

37.39M

106.16%

-1.26M

2023Q2

224

35.30M

102.90%

-4.83M

2023Q1

220

33.02M

96.37%

-5.12M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Cormorant Asset Management, LP

8.32M

12.1%

--

Mar 31, 2025

Suvretta Capital Management, LLC

6.80M

9.89%

+21.00K

+0.31%

Mar 31, 2025

Adage Capital Management, L.P.

6.20M

9.01%

+450.00K

+7.83%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.95M

7.19%

+206.82K

+4.36%

Mar 31, 2025

Franklin Advisers, Inc.

4.12M

5.99%

+9.56K

+0.23%

Mar 31, 2025

The Vanguard Group, Inc.

3.82M

5.55%

+31.14K

+0.82%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

3.71M

5.39%

+2.50K

+0.07%

Mar 31, 2025

TCG Crossover Management, LLC

3.57M

5.19%

--

Mar 31, 2025

Citadel Advisors LLC

2.29M

3.32%

-180.78K

-7.33%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.59M

2.32%

+54.13K

+3.52%

Mar 31, 2025

Related ETFs

Name

Proportion

No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Date

Type

Ratio

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

13.760USD

EyePoint Pharmaceuticals Inc

13.760

Overview

Company

Financials

Analysis